Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1996 Mar;3(2):236–238. doi: 10.1128/cdli.3.2.236-238.1996

Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins.

P Palmer 1, C Pallier 1, M Leruez-Ville 1, M Deplanche 1, F Morinet 1
PMCID: PMC170288  PMID: 8991644

Abstract

Human parvovirus B19 recombinant VP1 and VP2 capsid proteins were produced by a procaryotic pGEX expression plasmid to evaluate the humoral response by immunoblot assay in 14 patients with primary infection. The same concentrations of VP1 and VP2 recombinant proteins were used. This demonstrates that VP1 immunoglobulin M detection and/or VP1 immunoglobulin G seroconversion is a reliable marker of primary infections. Consequently, detection of antibodies to B19 VP1 might be helpful for identifying patients at risk for chronic B19 infection or patients who are susceptible to viral reinfection.

Full Text

The Full Text of this article is available as a PDF (181.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson M. J., Higgins P. G., Davis L. R., Willman J. S., Jones S. E., Kidd I. M., Pattison J. R., Tyrrell D. A. Experimental parvoviral infection in humans. J Infect Dis. 1985 Aug;152(2):257–265. doi: 10.1093/infdis/152.2.257. [DOI] [PubMed] [Google Scholar]
  2. Bansal G. P., Hatfield J. A., Dunn F. E., Kramer A. A., Brady F., Riggin C. H., Collett M. S., Yoshimoto K., Kajigaya S., Young N. S. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis. 1993 May;167(5):1034–1044. doi: 10.1093/infdis/167.5.1034. [DOI] [PubMed] [Google Scholar]
  3. Belloy M., Morinet F., Blondin G., Courouce A. M., Peyrol Y., Vilmer E. Erythroid hypoplasia due to chronic infection with parvovirus B19. N Engl J Med. 1990 Mar 1;322(9):633–634. doi: 10.1056/NEJM199003013220916. [DOI] [PubMed] [Google Scholar]
  4. Cohen B. J., Mortimer P. P., Pereira M. S. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J Hyg (Lond) 1983 Aug;91(1):113–130. doi: 10.1017/s0022172400060095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Courouce A. M., Ferchal F., Morinet F., Muller A., Drouet J., Soulier J. P., Perol Y. Human parvovirus infections in France. Lancet. 1984 Jan 21;1(8369):160–160. doi: 10.1016/s0140-6736(84)90086-2. [DOI] [PubMed] [Google Scholar]
  6. Gray J. J., Cohen B. J., Desselberger U. Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity. J Virol Methods. 1993 Sep;44(1):11–23. doi: 10.1016/0166-0934(93)90003-a. [DOI] [PubMed] [Google Scholar]
  7. Kurtzman G. J., Cohen B. J., Field A. M., Oseas R., Blaese R. M., Young N. S. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest. 1989 Oct;84(4):1114–1123. doi: 10.1172/JCI114274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Leruez M., Pallier C., Vassias I., Elouet J. F., Romeo P., Morinet F. Differential transcription, without replication, of non-structural and structural genes of human parvovirus B19 in the UT7/EPO cell as demonstrated by in situ hybridization. J Gen Virol. 1994 Jun;75(Pt 6):1475–1478. doi: 10.1099/0022-1317-75-6-1475. [DOI] [PubMed] [Google Scholar]
  9. Ozawa K., Ayub J., Young N. Translational regulation of B19 parvovirus capsid protein production by multiple upstream AUG triplets. J Biol Chem. 1988 Aug 5;263(22):10922–10926. [PubMed] [Google Scholar]
  10. Rosenfeld S. J., Yoshimoto K., Kajigaya S., Anderson S., Young N. S., Field A., Warrener P., Bansal G., Collett M. S. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest. 1992 Jun;89(6):2023–2029. doi: 10.1172/JCI115812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sato H., Hirata J., Furukawa M., Kuroda N., Shiraki H., Maeda Y., Okochi K. Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19. J Virol. 1991 Apr;65(4):1667–1672. doi: 10.1128/jvi.65.4.1667-1672.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schwarz T. F., Roggendorf M., Deinhardt F. Human parvovirus B19: ELISA and immunoblot assays. J Virol Methods. 1988 Jun;20(2):155–168. doi: 10.1016/0166-0934(88)90149-8. [DOI] [PubMed] [Google Scholar]
  13. Shade R. O., Blundell M. C., Cotmore S. F., Tattersall P., Astell C. R. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol. 1986 Jun;58(3):921–936. doi: 10.1128/jvi.58.3.921-936.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988 Jul 15;67(1):31–40. doi: 10.1016/0378-1119(88)90005-4. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES